everyone, financial second Great. I'll thank the results. Good call. Joe. our our for joining again, review of Thank you, with quarter you, morning, start adjusted and
in quarter with quarter of These it difficult period. X% which a Second expectations. line organic our in comparable $XXX record were a prior the were growth million with sales year against made results
$X.XX $XX earnings per leverage We're a reported We adjusted organically share year-over-year of adjusted or and basis. basis. X% strong $X.XX on X% million adjusted or a continuing increasing EBITDA XX% income reported with to drive net delivered diluted on up of
detail income our turn To adjusted X. provide growth, attention on some please slide to you your net
and driven XX% headwinds. and management million our $X in adjusted imperatives year-over-year, reported by inflation price form Our This the was SG&A reported increased net on second strategic up income growth sales. improvements flat productivity, generated both by on quarter expense operational traction offsetting of
the year our adding be As imperatives. strategy, half manufacturing of and the in excellence resources the invest to we will drive we to second continue growth in
exchange that year did unfavorable repeat. not benefit due last currency Foreign was a to
second debt the management. through our XXXX, million by quarter and interest $X down tax we rate effective of the XX.X% to rate XX.X% in second quarter to XX.X%, expect Year-to-date We We expense XXXX. our effective total of improved within interest to in our from continue reduced lower tax remain XX.X% XX.X%. adjusted and and guidance our the rate adjusted of year is
may this meaningful which purchasing the an XX and how is of from to product our our organic indicator resulting performing the reflects anomalies decisions. remind market growth quarter, We are slide review a versus turn timing To the of we everyone, individual let's sales. trailing results. more line contain four-quarter sales trend customer Now believe in of
As quarter. The quarter this outlook. rate our is slower chart the growth second full resulted tough comparable trend a year of with previously discussed, this consistent on in
So, let's of turn for discussions specific the more product line. context, to each
heart to XX, slowed Vascular growth On of markets expected impact by slide offset vascular organic in maturing cycle supplier item. peripheral growth in life Cardio sales an X% quality structural and quarter & a in was electrophysiology and second a the strong the related
to We and as be of the rest much the rate year-over-year we the third offsets of similar growth the expect its maturing see decline quarter quarter across highest electrophysiology second the product to the program market reaches line. growth
from issue Cardio supplier customer of programs. other the Vascular resolution the quality expect impact we maturing quarter, and fourth growth program, of lower acceleration the improve & the the electrophysiology the of In to
and second On neuromodulation. growth year low product the to sales lines prior and down due next in difficult slide, quarter, X% primarily in comparables the were in our neuromodulation cardiac
second orders been quarter, neuromodulation market the our impacted customers have by were our the slower During demand reporting. that
double-digit total single-digit low we year growth. from have result, As reduced high to neuromodulation our sales outlook a
In terms growth given market, modest finished the the CRM to continue of forecast We're this device we outlook the in supply our year. confident for agreements.
part segment. Slide XX the last shows of medical our
product shown with July Portable & line under includes The You'll our product recall in Viant Viant. sales Surgical line. supply Advanced XXXX, AS&O Medical acquired today Orthopedics agreements
partially offset Orthopedics increasing in by Second quarter & Medical. Portable products, a was decline down Surgical in due to demand Advanced
and Portable Medical. in launches new product second strong a expect both We half product from AS&O demand
finally, from and penetration our Electrochem, XX segment. demand grew as energy the a in non-medical the strong summarizes customer in Electrochem sales increased XX% And markets. we second quarter slide expected
We product new in initiatives. continue growth and customer increased the from second expect strong new launches, half to military growth demand
Let's our XXXX to turn outlook.
sales full full This range. for and well impacting year to is growth X% the delays Our neuromodulation of our as has the to single-digits. the revised high of program been maturing unchanged. rate Both Vascular of the absorbed electrophysiology factored year outlook supplier holding the we as in X% acceleration quality have are impact Cardio outlook growth & the and
the supply agreements, quarter of neuro we into electrophysiology of the Taking strong fourth timing expect terms maturing account and sales. program the the
performance growth confidence half our of $XXX operational first X% XX%. million, to $XXX Our is a range to adjusted a gives which to of to us increase EBITDA guidance million
we addition XX% our further improvement, EBITDA Accordingly, to new EPS $X.XX expected to guidance outlook. earnings reduction improvement by $X.XX the $X.XX range increased tax XX%. the growth previous per in continued efforts a of $X.XX, of drive In expenses a the $X.XX share to in our our adjusted interest to planning have to of and from reflecting
bringing our million and cash in second flow cash from the to slide operations XX, year-to-date with line in strong our million. We $XX total $XX expectations. Turning quarter delivered was flow to
reducing down the debt times paid payments our adjusted quarter debt to EBITDA. million the X.X $XX bringing million in leverage second to year-to-date in We and also $XX
full our and track on year outlook remain is unchanged. We
cash of expenditures $XX $XXX million. and of $XXX operations $XXX to from million million, and free to Capital million $XX in cash are to to between expect $XXX to million million range We flow expected to million generate expected million $XX tax be be cash $XX of and flow. are a payments
As to we execute our X.X growth to times EBITDA. range continue leverage add acquisitions debt expect X.X strategy and to we identify our the of capability, in remain to bolt-on
turn back to final his the now will call I for Joe comments.